Quick Dispatch:
Your eccogene glp 1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your eccogene glp 1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies ships.
Need Help?
Questions about eccogene glp 1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for eccogene glp 1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies in your area.
China's Eccogene Inks USD2 Billion Obesity Drug Deal With AstraZeneca
27.59
Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases
24.31
Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist - Haggag - 2025 - Diabetes, Obesity and Metabolism
20.53
GLP-1s: The Second Serving
26.25
GLP-1 and Anesthesia: Considerations and Cautions for CRNAs
23.41
Oral GLP-1 Market to Rise at 35.05% CAGR till 2035
28.19
The Multi-Sector Impacts of GLP-1RA Drugs
22.96
